Recent Finacing
Recent Raise
Axonis develops oral small-molecule KCC2 potentiators and neuromodulating therapies to restore excitation–inhibition balance and regenerate neurons for epilepsy, chronic pain, spinal cord injury, and neurodevelopmental disorders.
